Skip to content

Clinical study for botulinum toxin A in the treatment of androgenic alopecia

Clinical study for botulinum toxin A in the treatment of androgenic alopecia

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900021776
Enrollment
Unknown
Registered
2019-03-09
Start date
2019-03-05
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Androgenic Alopecia

Interventions

Case series:Subcutaneous injection of botulinum A

Sponsors

Shanghai Sixth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
20 Years to 50 Years

Inclusion criteria

Inclusion criteria: Men aged between 20 and 40 years old, who were diagnosed as androgen alopecia according to the diagnostic criteria of androgen alopecia, below grade V of alopecia grade, and those with severe alopecia were excluded from the experimental consideration due to poor results of previous experiments.

Exclusion criteria

Exclusion criteria: (1) face ministry has skin damage; (2) neuromuscular diseases such as myasthenia gravis, multiple sclerosis; (3) eyelid disease such as ptosis is prohibited; (4) clinical application of aminoglycoside antibiotics is prohibited, because it may destroy the role of BTX in the synapse; (5) those who are allergic to albumin or have allergic constitution are forbidden; (6) severe cardiac, hepatic and renal dysfunction; (8) connective tissue disease is forbidden.

Design outcomes

Primary

MeasureTime frame
The district photos;

Countries

China

Contacts

Public ContactYangsonglin

Shanghai Sixth People's Hospital

slyang@sjtu.edu.cn+86 18930177426

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026